ENDRA Life Sciences Inc
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source comprising radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic… Read more
ENDRA Life Sciences Inc (NDRA) - Total Liabilities
Latest total liabilities as of September 2025: $1.79 Million USD
Based on the latest financial reports, ENDRA Life Sciences Inc (NDRA) has total liabilities worth $1.79 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ENDRA Life Sciences Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how ENDRA Life Sciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ENDRA Life Sciences Inc Competitors by Total Liabilities
The table below lists competitors of ENDRA Life Sciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guideline Geo AB (publ)
ST:GGEO
|
Sweden | Skr30.71 Million |
|
Konsolidator AS
CO:KONSOL
|
Denmark | Dkr29.28 Million |
|
Nfc PLC
BK:NFC
|
Thailand | ฿6.29 Billion |
|
Asuransi Jasa Tania Tbk
JK:ASJT
|
Indonesia | Rp255.97 Billion |
|
Damartex
PA:ALDAR
|
France | €352.63 Million |
|
Curanex Pharmaceuticals Inc Common Stock
NASDAQ:CURX
|
USA | $185.96K |
Liability Composition Analysis (2014–2024)
This chart breaks down ENDRA Life Sciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 10.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.91 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ENDRA Life Sciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ENDRA Life Sciences Inc (2014–2024)
The table below shows the annual total liabilities of ENDRA Life Sciences Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.89 Million | +72.76% |
| 2023-12-31 | $1.10 Million | -47.08% |
| 2022-12-31 | $2.07 Million | -0.99% |
| 2021-12-31 | $2.09 Million | +31.01% |
| 2020-12-31 | $1.60 Million | -33.94% |
| 2019-12-31 | $2.42 Million | +147.86% |
| 2018-12-31 | $974.58K | +14.90% |
| 2017-12-31 | $848.21K | -38.74% |
| 2016-12-31 | $1.38 Million | +485.62% |
| 2015-12-31 | $236.42K | +142.23% |
| 2014-12-31 | $97.60K | -- |